343-53-3

Basic information

• Product Name: Naphthalene, 1-bromo-3-fluoro-
• Synonyms: 3-Fluor-1-bromnaphthalin;1-Bromo-3-fluoro-naphthalene;1-Brom-3-fluornaphthalin;3-Fluor-1-brom-naphthalin
• CAS NO: 343-53-3
• Molecular Formula: C10H6BrF
• Molecular Weight: 225.06
• Mol File: 343-53-3.mol
• Article Data: 3

Chemical Properties

• Melting Point: 31.5 °C (petroleum ether)
• Boiling Point: 84-88 °C(Press: 1 Torr)
• Density: 1.563±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Naphthalene, 1-bromo-3-fluoro-(CAS DataBase Reference)
• NIST Chemistry Reference: Naphthalene, 1-bromo-3-fluoro-(343-53-3)
• EPA Substance Registry System: Naphthalene, 1-bromo-3-fluoro-(343-53-3)

Safety Data

• Hazardous Substances Data: 343-53-3(Hazardous Substances Data)

Upstream product

• 13772-64-0 3-fluoronaphthalen-1-ylamine 
• 7499-65-2 4-bromo-2-nitronaphthalene 
• 90767-01-4 4-bromo-2-nitro-1-naphthylamine 
• 7499-73-2 N-(4-bromo-2-nitronaphthalen-1-yl)acetamide 
• 91394-66-0 1-(acetylamino)-4-bromonaphthalene 
• 2298-07-9 4-Bromo-1-naphthylamine 
• 179897-90-6 1,3-dibromo-2-chloro-5-fluoro-benzene 
• 88790-90-3 methyl 3-amino-5,6,7,8-tetrahydro-1-naphthoate 
• 13772-63-9 methyl 3-nitro-5,6,7,8-tetrahydro-1-naphthoate 
• 575-07-5 3-fluoronaphthalene-1-carboxylic acid 
• 4507-84-0 3-nitro-1-naphthoic acid 
• 74924-94-0 4-bromonaphthalene-2-amine 

Downstream Products

• 3109-48-6 2-<3-Fluor-naphthyl-(1)-methyl>-benzoesaeure 
• 668-84-8 4-(3-Fluoro-1-naphthoyl)-7-methylhydrindene 
• 1425-98-5 3-Fluor-1-o-toluoyl-naphthalin 
• 3799-79-9 2-(3-Fluor-naphthoyl-⁽¹⁾)-benzoesaeure 

Relevant articles and documents

Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5?MTA Complex for the Treatment of MTAP-Deleted Cancers

The PRMT5?MTA complex has recently emerged as a new synthetically lethal drug target for the treatment of MTAP-deleted cancers. Here, we report the discovery of development candidate MRTX1719. MRTX1719 is a potent and selective binder to the PRMT5?MTA complex and selectively inhibits PRMT5 activity in MTAP-deleted cells compared to MTAP-wild-type cells. Daily oral administration of MRTX1719 to tumor xenograft-bearing mice demonstrated dose-dependent inhibition of PRMT5-dependent symmetric dimethylarginine protein modification in MTAP-deleted tumors that correlated with antitumor activity. A 4-(aminomethyl)phthalazin-1(2H)-one hit was identified through a fragment-based screen, followed by X-ray crystallography, to confirm binding to the PRMT5?MTA complex. Fragment growth supported by structural insights from X-ray crystallography coupled with optimization of pharmacokinetic properties aided the discovery of development candidate MRTX1719.

MTA-Cooperative PRMT5 Inhibitors

The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.